GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cel-sci Corporation (CVM) [hlAlert]

Rating:
Buy CVM
down 51.85 %

Cel-sci Corporation (CVM) rated Buy with price target $3 by Dawson James

Posted on: Monday,  Mar 2, 2015  9:25 AM ET by Dawson James

Dawson James rated Buy Cel-sci Corporation (AMEX: CVM) on 03/02/2015, when the stock price was $1.08. Since
then, Cel-sci Corporation has lost 51.85% as of 08/27/2015's recent price of $0.52.
If you would have followed this Dawson James's recommendation on CVM, you would have lost 51.85% of your investment in 178 days.

CEL-SCI Corporation, is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is immunotherapy, incorporating both active and passive immune activity.

Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology with a staff of over 50 investment professionals ensures our clients stay ahead of the constant changes in the healthcare capital markets. From our widely-respected institutional research, investment banking and high net worth services to our personalized attention for individual accounts, we provide quality service for our clients. We take pride in the quality and depth of our professionals and encourage you to contact us so we can begin serving your financial needs today.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/2/2015 9:25 AM Buy
None
1.08 3.00
as of 8/27/2015
1 Week down  -1.88 %
1 Month down  -16.12 %
3 Months down  -40.22 %
1 YTD down  -51.85 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy